
The surface antigen of hepatitis B virus (HBsAg) is the main serological marker of HBV infection since its discovery almost 50 years ago. Currently the quantification of HBsAg has acquired special relevance as there are commercial tests to measure its levels. Several studies have shown that in patients treated with pegylated interferon alfa the fall of HBsAg levels predicts the loss of HBsAg and persistent virologic response. The role of the quantification of HBsAg in the treatment with nucleoside analogues is still not well understood and requires further studies.
Hepatitis B virus, Hepatitis B Surface Antigens, Interferon-alpha, Interferon alpha-2, Viral Load, Antiviral Agents, Recombinant Proteins, Polyethylene Glycols, Hepatitis B, Chronic, Treatment Outcome, Humans, Drug Monitoring, Biomarkers
Hepatitis B virus, Hepatitis B Surface Antigens, Interferon-alpha, Interferon alpha-2, Viral Load, Antiviral Agents, Recombinant Proteins, Polyethylene Glycols, Hepatitis B, Chronic, Treatment Outcome, Humans, Drug Monitoring, Biomarkers
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 6 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
